Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients

Clinical Infectious Diseases

Volumn 56, Issue 8, 2013, Pages 1117-1122

  Vispo, Eugenia ^a   Cevik, Muge ^b   Rockstroh, Juergen K ^c   Barreiro, Pablo ^a   Nelson, Mark ^b   Scourfield, Andrew ^b   Boesecke, Christoph ^c   Wasmuth, Jan Christian ^c   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

didanosine; gene polymorphisms; HIV; noncirrhotic portal hypertension; pharmacogenomics

Indexed keywords

5' NUCLEOTIDASE; 5' NUCLEOTIDASE CYTOSOLIC II; DIDANOSINE; INOSINE TRIPHOSPHATASE; PHOSPHATASE; PURINE NUCLEOSIDE PHOSPHORYLASE; UNCLASSIFIED DRUG; VIRUS RNA; XANTHINE OXIDASE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; GENDER; GENE FREQUENCY; GENETIC RISK; GROUPS BY AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC DISEASE; IDIOPATHIC NONCIRRHOTIC PORTAL HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PHARMACOGENOMICS; PORTAL HYPERTENSION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD;

5'-NUCLEOTIDASE; ADULT; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; DIDANOSINE; FEMALE; GENETIC ASSOCIATION STUDIES; GPI-LINKED PROTEINS; HIV INFECTIONS; HUMANS; HYPERTENSION, PORTAL; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RISK; XANTHINE OXIDASE;

EID: 84875645759     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit001     Document Type: Article

References (30)

1. Nuñez M. Clinical syndromes and consequences of antiretroviralrelated hepatotoxicity. Hepatology 2010; 52:1143-55.
2. Soriano V, Puoti M, Garcia-Gascó P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22:1-13. (Pubitemid 350301936)
3. Maida I, Núñez M, Ríos MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006; 42:177-82. (Pubitemid 43884712)
4. Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 21:187-92. (Pubitemid 46036926)
5. Schiano T, Kotler D, Ferran E, Fiel M. Hepatoportal sclerosis as a cause of non-cirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007; 102:2536-40. (Pubitemid 47631766)
6. Saifee S, Joelson D, Braude J, et al. Non-cirrhotic portal hypertension in patients with HIV-1 infection. Clin Gastroenterol Hepatol 2008; 6:1167-9.
7. Kovari H, Ledergerber B, Peter U, et al. Association of non-cirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009; 49:626-35.
8. Mendizabal M, Craviotto S, Chen T, Silva M, Reddy K. Non-cirrhotic portal hypertension: another cause of liver disease in HIV patients. Ann Hepatol 2009; 8:390-5.
9. Maida I, Garcia-Gasco P, Sotgiu G, et al. Antiretroviral-Associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008; 13:103-7. (Pubitemid 351541679)
10. Scourfield A, Waters L, Holmes P, et al. Non-cirrhotic portal hypertension in HIV-infected individuals. Int J STD AIDS 2011; 22:324-8.
11. Saison J, Cotte L, Chidiac C, Ferry T. Fatal cumulative toxicities of HAART in a stable, AIDS-free, HIV-infected patient. BMJ Case Rep. In press.
12. Jackson B, Doyle J, Hoy J, et al. Non-cirrhotic portal hypertension in HIV mono-infected patients. J Gastroenterol Hepatol 2012; 27:1512-9.
13. Cotte L, Bénet T, Billioud C, et al. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study. J Hepatol 2011; 54:489-96.
14. Seiderer J, Zech C, Diebold J, et al. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur J Gastroenterol Hepatol 2006; 18:553-5. (Pubitemid 43832759)
15. Gisbert JP, González-Lama Y, Maté J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007; 102:1518-27. (Pubitemid 46976279)
16. Tuyama A, Krakauer M, Alzaabi M, Fiel M, Legnani P, Schiano T. Mercaptopurine-induced hepatoportal sclerosis in a patient with Crohn's disease. J Crohn Colitis. In press.
17. Vispo E, Moreno A, Maida I, et al. Non-cirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS 2010; 24:1171-6.
18. O'Connell J, Weeks D. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet 1998; 63:259-66. (Pubitemid 30428342)
19. Asimit J, Zeggini E. Rare variant association analysis methods for complex traits. Annu Rev Genet 2010; 44:293-308.
20. Barreiro P, Vispo E, Labarga P, Soriano V. Management and treatment of chronic hepatitis C in HIV patients. Semin Liver Dis 2012; 32:138-46.
21. Vispo E, Morello J, Rodriguez-Novoa S, Soriano V. Non-cirrhotic portal hypertension in HIV infection. Curr Opin Infect Dis 2011; 24:12-8.
22. Shastri S, Dubinsky M, Poordad F, Vasiliauskas E, Geller S. Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy. Arch Pathol Lab Med 2004; 128:49-53. (Pubitemid 38049566)
23. Chouchana L, Narjoz C, Beaune P, Loriot M, Roblin X. The benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35:15-36.
24. Sabin C, Worm S, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417-26.
25. Kuller L, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
26. Strategies for Management of Antiretroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22: F17-24.
27. Higgs J, Payne K, Roberts C, Newman W. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 2009; 11:177-88.
28. Fellay J, Thompson A, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464:405-8.
29. Vispo E, Maida I, Barreiro P, Moreno V, Soriano V. Upper gastrointestinal bleeding may unmask didanosine-Associated portal hepatopathy in HIV/HCV co-infected patients. HIV Clin Trials 2008; 9:440-4.
30. Casals F, Bertranpetit J. Human genetic variation, shared and private. Science 2012; 337:39-40.